Physician profile
Lorraine E Kryvicky
NPI 1164458691
$8,903.06
in general payments reported to CMS, 2019-2025
34 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,148 · 2022: $1,616 · 2023: $1,814 · 2024: $2,133 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,839 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,838.61 |
| Education | $299.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,639.02 | 2021-2025 | |
| Galderma Laboratories, L.P. | $878.22 | 2021-2025 | Aklief, Nemluvio |
| Janssen Biotech, INC. | $743.06 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $617.31 | 2022-2025 | Dupixent |
| Genzyme Corporation | $497.18 | 2022-2025 | |
| Pfizer INC. | $453.66 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $450.79 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $405.25 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $392.65 | 2021-2025 | Absorica Ld, Winlevi, Blu-U |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.77 | 2022-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $337.43 | 2021-2025 | |
| Ucb, INC. | $330.06 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $291.42 | 2022-2025 | Opzelura |
| Biohaven Pharmaceuticals, INC. | $175.83 | 2021 | |
| Amgen INC. | $167.12 | 2022-2025 | Otezla, Otezla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $163.45 | 2024-2025 | Zoryve |
| Almirall LLC | $133.11 | 2021-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $123.11 | 2021-2025 | Adbry, Spevigo, Anzupgo |
| Dermavant Sciences, INC. | $98.74 | 2023-2024 | Vtama |
| Allergan, INC. | $93.83 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $84.04 | 2022-2025 | Belbuca, Xtampza |
| Vyne Pharmaceuticals INC. | $67.47 | 2021 | |
| Botanix Sb INC | $60.18 | 2025 | Sofdra |
| Lnhc, INC | $57.89 | 2025 | Zelsuvmi |
| Merz North America, INC. | $54.46 | 2021-2022 | |
| Revance Therapeutics, INC. | $47.93 | 2025 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.90 | 2023-2024 | Arazlo, Jublia, Cabtreo |
| Verrica Pharmaceuticals INC. | $26.56 | 2024 | Ycanth |
| Journey Medical Corporation | $26.37 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $23.20 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.81 | 2022 | |
| Nabriva Therapeutics, Plc | $18.19 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.06 | 2023 | Seglentis |
| Hill Dermaceuticals, INC. | $11.99 | 2024 | Tolak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Kryvicky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.